Immunology for
a Better Future
Learn More
Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.
Learn More
We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.
Learn More
Advancing Therapeutic
Solutions
Our lead program, Ampligen®, is an immuno-modulator that has shown broad spectrum activity in in-vitro and animal testing and is being evaluated in clinical studies for a range of debilitating and life-threatening conditions.
Learn More
Focused on Improving
Lives
We are working to develop solutions that have the potential to help patients across a number of disease areas, including oncology, immune disorders and viral diseases.
Learn More
Key Highlights
AIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination Therapy
OCALA, Fla., July 24, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the publication of new pre-clinical data concerning the company's drug Ampligen as part of a combinational therapy in the treatment of melanoma, showing...
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., July 03, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, AIM Chief Executive Officer Thomas Equels provided an...
AIM ImmunoTech to Participate in the Virtual Investor Pitch Conference
Live video webcast on Monday, June 17th at 1:00 PM ETOCALA, Fla., June 10, 2024 -- AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor...